{"preliminary_commentary":{"by_channel":{"youtube":14,"x_thread":9,"podcast":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04055493\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ADAPTcycle","nct_id":"NCT04055493","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=adaptcycle-nct04055493. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ADAPTcycle","arms":[{"description":"Ribociclib 600mg / day over 26 cycles + endocrine treatment of physician´s choice","label":"Ribociclib plus ET","type":"EXPERIMENTAL"},{"description":"Standard-of-care chemotherapy according to the clinical guidelines, e.g., of the Breast Committee of the German Gynecological Oncology Group (AGO), and regional prescribing information depending on patient's needs for 16-24 weeks,","label":"Standard-of-care chemotherapy","type":"NO_INTERVENTION"}],"collaborators":["Novartis","Genomic Health®, Inc."],"completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"conditions":["Breast Cancer Female"],"enrollment":{"count":1684,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ribociclib 200Mg Oral Tablet","otherNames":["Kisqali"],"type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"Women's Cancer Study Group GmbH","official_title":"Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Endocrine Therapy Plus Ribociclib Versus Chemotherapy in Intermediate Risk, HR+/HER2- Early Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"invasive disease-free survival (iDFS)","timeFrame":"at end of study, on average 5 years after start of treatment"},{"measure":"distant disease-free survival (dDFS)","timeFrame":"at end of study, on average 5 years after start of treatment"}],"references":[{"citation":"Klier K, Patel YJ, Schinkothe T, Harbeck N, Schmidt A. Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study. JMIR Cardio. 2023 Sep 11;7:e48096. doi: 10.2196/48096.","pmid":"37695655","type":"DERIVED"}],"start_date":{"date":"2019-07-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC","url":"https://clinicaltrials.gov/study/NCT04055493"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/adaptcycle-nct04055493"}